In this otherwise optimistic scenario, the potential of GLP1-RAs to protect against AF onset is still uncertain: Monami et al. [94] found that GLP1-RA administration did not influence AF onset, a finding consistent with results reported by Chan et al. [95] and a subanalysis of the REWIND trial (which compared dulaglutide vs. a placebo in patients with T2DM) [96]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.